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Abstract
 
c-Jun NH
 
2
 
-terminal kinases (JNK) play important roles in T helper cell (Th) proliferation,
differentiation, and maintenance of Th1/Th2 polarization. To determine whether JNKs are
involved in antiviral T cell immunity, and whether JNK1 and JNK2 bear biological differences,
we investigated the immune responses of JNK1-deficient and JNK2-deficient mice to lympho-
cytic choriomeningitis virus (LCMV). After LCMV infection, wild-type (JNK
 
 
 
/
 
 
 
) mice had a
5- to 10-fold increase in splenic CD8
 
 
 
 T cells. In contrast, infected JNK1
 
 
 
/
 
 
 
 mice showed a
significantly lower virus-specific CD8
 
 
 
 T cell expansion. However, JNK1
 
 
 
/
 
 
 
 mice cleared
LCMV infection with similar kinetics as JNK
 
 
 
/
 
 
 
 mice. Splenic T cells from LCMV-infected
JNK1
 
 
 
/
 
 
 
 animals produced interferon 
 
 
 
 after stimulation with viral peptides. However, fewer
JNK1
 
 
 
/
 
 
 
 T cells acquired an activated phenotype (CD44
 
hi
 
) and more JNK1
 
 
 
/
 
 
 
CD8
 
 
 
CD44
 
hi
 
cells underwent apoptosis than JNK
 
 
 
/
 
 
 
 cells at the peak of the primary response. In contrast,
LCMV-infected JNK2
 
 
 
/
 
 
 
 mice generated more virus-specific CD8
 
 
 
 T cells than JNK
 
 
 
/
 
 
 
mice. These results indicate that JNK1 and JNK2 signal pathways have distinct roles in T cell
responses during a viral infection. JNK1 is involved in survival of activated T cells during
 
immune responses, and JNK2 plays a role in control of CD8
 
 
 
 T cell expansion in vivo.
Key words: viral infection • cellular activation • T lymphocytes • protein kinases • 
lymphocytic choriomeningitis virus
 
Introduction
 
Immune responses are mediated via cell-to-cell contact or
secretion of soluble mediators. In both instances, receptor
molecules transmit this information from the cell’s surface
to its interior, thereby transducing a cascade of intracellular
events. Numerous cellular receptors on the T cell surface
have been studied for their role in immune responses;
however, the signaling pathways activated after ligands
bind to such receptors are not completely understood. Mi-
 
togen-activated protein (MAP)
 
*
 
 kinase signaling pathways
are involved in control of immune responses (1, 2). MAP
kinases link cell-surface receptors to regulatory intracellular
targets leading to the control of pivotal processes such as
gene expression, cell proliferation and motility, cell sur-
vival, and death (3). At least four groups of MAP kinases
are expressed in mammals: extra cellular signal–related ki-
nases (ERK) 1–2, ERK5, p38 proteins, and c-Jun NH
 
2
 
-
terminal kinases (JNK1/2/3; reference 3).
The JNKs, also known as stress-activated protein kinases,
phosphorylate the transcription factors c-Jun (part of AP-1
complex), JunD, ATF2, ATFa, Elk-1, Sap-1, nuclear factor
of activated T cells (NFAT)c1, and NFAT4 (1, 2, 4, 5).
Three JNK genes have been identified: JNK1, JNK2, and
JNK3, and their alternative splicing results in at least 10 iso-
forms of JNK (6). JNK1 and JNK2 are ubiquitously ex-
pressed, whereas JNK3 is expressed mainly in brain, testis,
and heart. JNK is involved in cell death, proliferation, and
differentiation as well as cells’ response to stress such as ul-
traviolet light and proinflammatory molecules. Although
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virus; MAP, mitogen-activated protein. 
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lymphocyte development is normal in JNK1-deficient (
 
 
 
/
 
 
 
)
mice (7) and JNK2
 
 
 
/
 
 
 
 mice (8), differences in lymphocyte
responses have been observed. For example, when naive
CD4
 
 
 
 T cells are stimulated in vitro with polyclonal anti-
bodies (against CD3 and CD28) or mitogen, these cells
from JNK1
 
 
 
/
 
 
 
 mice preferentially differentiate into a Th2
phenotype and show a decreased activation-induced cell
death (7), whereas CD4
 
 
 
 T cells from JNK2
 
 
 
/
 
 
 
 mice show
impaired IFN-
 
 
 
 production and a diminished Th1 re-
sponse (8). One in vivo consequence of such defects has
been shown to affect 
 
Leishmania major
 
 infection of JNK1
 
 
 
/
 
 
 
mice bred on a genetically resistant background. Such mice
fail to resolve the infection, showing enhanced, noncura-
tive Th2 Leishmania-specific responses (9). Hence, it is
thought that JNK1 MAP kinase is required for effective
polarization toward a Th1 response in vivo (9).
Because JNK has a critical role in Th activation and
JNK activity is also detectable in CD8
 
 
 
 T cells (see Conze
et al. in this issue [9a]), we evaluated the role of these
MAP kinases in physiological CD8
 
 
 
 T cell–mediated im-
mune responses. CD8
 
 
 
 T cells play a critical role in the
control of many viral pathogens, including lymphocytic
choriomeningitis virus (LCMV). LCMV is a natural
pathogen for mice. Because the T cell response to LCMV
is well characterized in mice, these mice have been used
extensively to explore molecular and cellular mechanisms
of viral clearance and viral persistence (for a review, see
reference 10) as well as regulation of the immune response
(11, 12) of both primary and memory phases. After infec-
tion with LCMV, adult immunocompetent mice mount a
robust virus-specific CD8
 
 
 
 T cell response that clears the
virus infection (13, 14). Kinetically during the LCMV in-
fection, the virus-specific CD8
 
 
 
 and CD4
 
 
 
 T cell popula-
tions expand (15–18), followed by a contraction phase in
which many of these cells die by apoptosis; a stable life-
long population of memory CD8
 
 
 
 T cells remains (18–
22), and a CD4
 
 
 
 T cell memory population declines
slowly (18). Further, the LCMV model has been used to
evaluate the physiological contributions of many soluble
mediators and cell-to-cell contact molecules to the antivi-
ral immune responses (23–30).
The role of MAP kinases in antiviral CD8
 
 
 
 and CD4
 
 
 
 T
cell immune responses has not previously been established.
In this paper, we evaluate the immune responses to LCMV
infection as influenced by JNK1 and JNK2 MAP kinases.
This was accomplished by study of mice genetically defi-
cient for either JNK1 or JNK2, by using staining of virus-
specific induced IFN-
 
 
 
 producing CD4
 
 
 
 and CD8
 
 
 
 T
cells and tetramer staining of viral-specific CD8
 
 
 
 T cells
(16, 17, 31). Our results reveal that JNK1 and JNK2 as-
sume distinctly different functions in CD8
 
 
 
 T cell activa-
tion and expansion.
 
Materials and Methods
 
Mice.
 
The generation, breeding, and use of JNK1 genetically
deficient (knockout; JNK1
 
 
 
/
 
 
 
), JNK2 genetically deficient
(JNK2
 
 
 
/
 
 
 
), and JNK
 
 
 
/
 
 
 
 mice has been described (7, 8). Mice in
 
each group were backcrossed to C57BL/6 for 6–8 generations.
Breeding and maintenance were performed under specific patho-
gen-free conditions at Scripps Research Institute (La Jolla, CA)
and at Yale University (New Haven, CT).
 
Virus, Virus Quantification, and Infection of Mice.
 
The Arm-
strong 53b strain (ARM) and the clone-13 (Cl-13) strain of
LCMV were used. Virus origins, sequence, growth in baby ham-
ster kidney cells, and titration by standard plaque assay on Vero
cells have been described (32, 33). Mice were infected when 8 to
15 wk of age by intraperitoneal route using 2 
 
 
 
 10
 
5
 
 PFU of
LCMV ARM or by intravenous route using 2 
 
 
 
 10
 
6
 
 PFU of
LCMV-Cl-13 in a volume of 0.2 ml. For analyzing immune
memory, mice were infected with 2 
 
 
 
 10
 
5
 
 PFU of LCMV ARM
intraperitoneally at least 60 d before the second infection with 2 
 
 
 
10
 
6
 
 PFU of LCMV-Cl-13 intravenously.
 
Peptides.
 
In vitro epitope-specific stimulation used MHC
class I–restricted peptides (glycoprotein [GP] amino acids [aa]
33–41 [KAVYNFATC] and nucleoprotein [NP] aa 396–404
[FQPQNGQFI]) obtained from Peptidogenic, and MHC class
II–restricted peptides (GP aa 61–80 [GLNGPDIYKGVYQFKS-
VEFD] and NP aa 309–328 [SGEGWPYIACRTSIVGRAWE])
obtained from Chiron Corp.
 
CTL Assay.
 
Primary LCMV-specific CTL activity of spleno-
cytes obtained from LCMV-infected mice was measured in a
standard 5-h 
 
51
 
Cr release assay as described (13). Briefly, 
 
51
 
Cr-
labeled Balb C17 (H-2
 
d
 
) and MC57 (H-2
 
b
 
) cells either uninfected
or infected with LCMV-ARM at a multiplicity of infection
(MOI) of 1 were used as targets 48 h later. Effector cells harvested
from spleens of LCMV-infected mice 7 d after infection were
added to LCMV infected or uninfected targets at ratios of 50:1,
25:1, and 12:1. Lysis was measured after a 5-h incubation period
at 37
 
 
 
C. Samples were set up in triplicate and variance was less
than 10%. The results are expressed as the percentage of specific
 
51
 
Cr release (13).
 
In Vitro Epitope-specific Stimulation.
 
Spleens were harvested
from JNK1
 
 
 
/
 
 
 
, JNK2
 
 
 
/
 
 
 
, and JNK
 
 
 
/
 
 
 
 mice at different time
points after infection. Cells in the spleen were obtained by teasing
apart spleens, passing the cells through a nylon mesh, and lysing
erythrocytes with 0.83% NH
 
4
 
Cl. When appropriate these cells
were cultured in RMPI (GIBCO BRL/LifeTechnologies) con-
taining 10 mM HEPES (GIBCO BRL), 50 U/ml penicillin
(GIBCO BRL), 50 
 
 
 
g/ml streptomycin (GIBCO BRL), 1 mM
sodium pyruvate (GIBCO BRL), 0.1 mM nonessential amino ac-
ids (GIBCO BRL), and 50 
 
 
 
M 2-mercaptoethanol. Cytokine in-
tracellular staining was performed on 10
 
6
 
 splenocytes stimulated
5 h with 1 
 
 
 
g/ml of MHC-class I peptide (NP aa 396–404 or GP
aa 33–41) or 2 
 
 
 
g/ml of MHC class II peptide (GP aa 61–80 or
NP aa 309–328) in the presence of 50 U/ml of recombinant hu-
man IL-2 (Roche) and 1 
 
 
 
g/ml or 5 
 
 
 
g/ml of brefeldin A
(Sigma-Aldrich).
 
Flow Cytometry.
 
Splenocytes were stained for cell surface an-
tigens, using anti-CD8 antibodies conjugated either to allophyco-
cyanin (APC), PE, or FITC, and anti-CD4 antibodies conjugated
either to Cychrome or FITC (BD PharMingen), for 20–30 min
on ice in PBS containing 1% (vol/vol) FBS and 0.1% (wt/vol)
NaN
 
3
 
. After, cells were washed two times, fixed, and permeabi-
lized in 4% (wt/vol) paraformaldehyde, and 0.1% (wt/vol) sapo-
nin in HBSS. Intracellular cytokine staining was accomplished
with incubation of antibodies to IFN-
 
 
 
 PE or IL-2-APC for 30
min on ice in 0.1% (wt/vol) saponin, 1% FBS PBS, followed by
two washes and resuspension of cells in 1% (vol/vol) FBS, 0.1%
(wt/vol) NaN
 
3
 
 PBS, as described (34). For annexin-V staining,
sodium azide was omitted in all buffers and cells were first stained 
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with surface markers (CD4, CD8, and CD44) and then exposed
to annexin-V–conjugated to PE and 7-amino-actinomycin D
(7-AAD; BD PharMingen) according to the manufacturer’s in-
structions. Cells were acquired on a FACSCalibur™ flow cytom-
eter (Becton Dickinson) and analyzed with CELLQuest™ (Bec-
ton Dickinson) and FlowJo (Treestar) software.
 
Statistical Analyses.
 
Data handling and analysis (Student’s 
 
t
 
test) were performed using Prism 3.0 (GraphPad Software).
 
Results
 
JNK1
 
 
 
/
 
 
 
 and JNK2 /  Mice Clear LCMV Equivalently
After an Acute Infection. First, we determined whether a
deficiency in the MAP kinases JNK1 or JNK2 would inter-
fere in the viral clearance of LCMV. After inoculation with
LCMV ARM intraperitoneally, JNK1 / , JNK2 / , and
JNK /  mice cleared all detectable virus from their sera by
8 d after infection (Table I) indicating that neither JNK1
nor JNK2 deficiencies prevented the clearance of over 3–4
logs of infectious virus.
Expansion of Virus-specific CD8  T Cells Is Increased in
JNK2 /  Mice during Acute LCMV Infection but CD8  T
Cell Immune Functions Are Normal in Both JNK1 /  and
JNK2 /  Mice. The rapid clearance of LCMV virus dur-
ing acute infection is mediated by the lytic activity of
CD8  CTL (35–37). Besides this lytic activity, CTL can
also secrete cytokines such as IFN   and IL-2 upon spe-
cific MHC-restricted TCR interaction (38). We tested for
these two activities in splenocytes prepared 7 d after
LCMV-ARM infection. T cells harvested from JNK1 / ,
JNK2 / , and JNK /  mice showed an efficient and
equivalent MHC-restricted virus specific killing, which
correlated directly with clearance of the virus from inocu-
lated mice (Table I).
The expansion of LCMV-specific T cells peaks at about
8 d after infection (16), and up to 70% of total CD8  T
cells are virus specific. Immunodominant epitopes for
C57BL/6 mice are GP aa 33–41 and NP aa 396–404. At
day 7 after infection, the resulting percentages of LCMV-
specific CD8  T cells after in vitro stimulation with GP aa
33–41 and NP aa 396–404 were similar for all groups (Fig.
1 and Table II). Interestingly, at day 8 after infection,
JNK2 /  mice showed a statistically significant increase (P  
0.05) in the relative expansion of virus specific CD8  T
cells when compared with JNK /  for both tested epitopes
(GP33–41 shown on Fig. 1 and Table II for NP396–404
and GP 33–41). Similar results were seen in two indepen-
dent experiments using 3–4 mice per group. In contrast,
JNK1 /  and JNK /  had similar percentages of virus-spe-
cific CD8  T cells for these peptides. T cells from naive
animals of all groups failed to produce IFN-  after LCMV-
peptide stimulation.
As IL-2 plays a role in T cell proliferation, and JNK af-
fects the stability of the IL-2 mRNA (39), we next evalu-
ated the percentage of IL-2 producing virus-specific T cells
in JNK1 / , JNK2 / , and JNK /  mice. IL-2–positive
CD8  T cells were also positive for IFN- . There was no
significant difference in the percentage of CD8  T cells se-
creting IL-2 after stimulation with either one of the two
major MHC class I–restricted immunodominant peptides
(see Table II). Additionally, when supernatants of spleno-
cytes stimulated with class I–restricted peptides (GP aa 33–
44 or NP aa 396–404) for 25–30 h were tested by ELISA,
JNK1 / , JNK2 / , and JNK /  cells secreted similar
amounts of IL-2 (data not shown). T cells from naive ani-
mals did not produce IL-2 when stimulated with LCMV-
specific MHC class I–restricted peptides. Furthermore,
CD25, the high affinity IL-2 receptor was similarly ex-
pressed on CD4  and CD8  T cells from LCMV-infected
JNK1   , JNK2   , and JNK /  mice (data not shown).
Virus-specific CD4  T Cell Immune Functions Are Normal
in JNK1 /  and JNK2 /  Mice Infected with LCMV.
Having studied CD8  T cell immune functions, we then
analyzed CD4  T cell functions by stimulating splenocytes
independently with two MHC class II–restricted immu-
nodominant epitopes of LCMV; GP aa 61–80 and NP aa
309–328 (40), and measuring the percentage of CD4  T
cells induced to produce IFN- . Previous studies showed
that over 10% of CD4  T cells can be recorded as virus-
specific after LCMV peptide stimulation (19). Stimulation
with GP aa 61–80 or NP aa 309–328 peptide resulted in
similar percentage of IFN-  producing CD4  T cells from
JNK1 /  and JNK /  mice. The percentage of CD4  T
cells secreting IFN-  after a GP aa 61–80 was higher for
JNK2 /  cells than for JNK /  cells.
The percentage of IL-2 secreting CD4  T cells after in
vitro stimulation with GP aa 61–80 and NP aa 309–328
Table I. Primary CTL Activity and Function Are Normal in 
JNK1 /  and JNK2 /  Animals
Specific 51Cr releasea
Group
Effector/
target ratio H-2b H-2d
Clearance of
LCMV
from serab
JNK1 /  50:1 35   4  1 4/4
25:1 23   3  1
12:1 14   4  1
JNK2 /  50:1 40   6  1 4/4
25:1 40   2  1
12:1 22   5  1
JNK /  50:1 27   4  1 4/4
25:1 22   3  1
12:1 14   2  1
aAverage of four mice per group, no statistical difference between
groups.
bTo evaluate clearance of infectious virus, sera were harvested 8 d after
LCMV inoculation while 2-3 d after inoculation with LCMV-ARM
2   105 PFU intraperitoneal viral titers range at 3 logs of infectious vi-
rus/ml of sera (references 23 and 34), at day 8 no detectable infectious
virus was observed in any of the sera by plaque assay (reference 32).804 JNK1 and JNK2 in Viral-specific CD8  T Cell Expansion
MHC class II peptides was assessed (see Table II). A greater
percentage of GP aa 61–80–specific CD4  T cells pro-
duced IL-2 from JNK2 /  mice when compared with
CD4  T cells from JNK /  mice, similar to results ob-
tained for IFN- . Furthermore, there was a dichotomy be-
tween responses to the GP (high response) and NP (low re-
sponse) CD4  T cell epitopes. When IL-2 secretion was
measured by ELISA after GP aa 61–80 stimulation for 25–
30 h, virus-specific JNK2 /  and JNK1 /  CD4  T cells
produced slightly more IL-2 than CD4  T cells from
JNK /  mice although the difference was not statistically
significant (data not shown, P   0.1). The mean fluores-
cence intensity was similar for IL-2 and IFN-  producing
CD4  T cells from all groups indicating comparable levels
of cytokine production.
Virus-specific T Cell Number Is Differentially Controlled in
JNK1 /  and JNK2 /  Mice During Acute LCMV Infec-
tion. During acute LCMV infection, spleens from JNK1 / 
never expanded to the size observed in JNK /  mice. We
hypothesized that the expansion of virus-specific T cells
Figure 1. After LCMV infection, the
percentage of virus specific splenic T cells is
higher in JNK2 / , but similar in JNK1 / 
and JNK /  mice. JNK1 / , JNK2 / , and
JNK /  animals were injected intraperito-
neally with LCMV ARM 2   105 PFU. 7
(D7) or 8 (D8) d after infection, spleens
were processed and stimulated for 5 h in vitro
with virus specific peptide GP aa 33–41.
Cells were then stained for CD8 and intra-
cellular IFN- . Values written in the dot
plots indicate the percentage of CD8  T
cells positive for IFN- .
Table II. Splenocytes from 7 and 8 d after LCMV Inoculation Were Stimulated In Vitro with LCMV-specific Peptides and Cytokine 
Production Was Assessed by Flow Cytometry
IFN-  IL-2
Percentage of splenic
CD8  T cellsa, b
Percentage of splenic
CD4  T cellsa, b
Percentage of splenic
CD8  T cellsa, b
Percentage of splenic
CD4  T cellsa, b
Group GP 33–41 NP 396–404 GP 61–80 NP 309–328 GP 33–41 NP 396–404 GP 61–80 NP 309–328
JNK1 /  D7 22   1 15   1 5.0   0.3 1.1   0.3 1.8   0.3 0.6   0.1 2.6   1 0.3   0.05
D8 36   1 18   1 4.9   0.5 1.7   0.2
JNK2 /  D7 26   2 18   2 7.4   1.3 1.5   0.2 1.2   0.1 0.6   0.1 4.5   0.5 0.3   0.05
D8 53   2c 29   3c 11.1   1.7d 1.8   0.4
JNK /  D7 23   1 14   1 6.1   1.0 1.4   0.5 1.4   0.1 0.3   0.03 3.6   0.5 1.0   0.4
D8 30   2 16   1 6.3   0.9 2.3   0.3
D7, day 7; D8, day 8.
aAverage of four mice per group.
bPercentage of CD8  or CD4  positive for cytokine as measured by flow cytometry   standard error.
cP   0.05 compared to JNK / .
dP   0.05.805 Arbour et al.
could be impaired in JNK1 /  mice. We therefore ana-
lyzed relative percentages of CD8  T cells and total num-
bers of CD8  and CD4  T cells per spleen. 7 d after
LCMV infection, JNK /  and JNK2 /  mice expanded
their CD8  T cell population from 16 to  40% (Fig. 2),
while JNK1 /  mice failed to display the degree of relative
expansion of splenic CD8  T cells. However, at 8 d after
LCMV-infection, the percentage of splenic CD8  T cells
in JNK1 /  reached a similar value as that of JNK2 /  and
JNK /  (35, 39, and 40%, respectively). However, upon
analysis of the total number of splenocytes, JNK1 /  had
50% fewer splenocytes (i.e., JNK /  mice: 8   107 cells/
spleen; JNK2 /  mice: 7   107 cells/spleen; JNK1 / : 3  
107 cells/spleen). From the total number of cells obtained
per spleen and the percentages of CD8  and CD4  T cells,
and the percentages of virus-specific T cells, the number of
T cells per spleen specific for each immunodominant viral
peptide can be calculated (Fig. 3). Thus, JNK1 /  had
lower total numbers of virus specific CD8  and CD4  T
cells than did JNK /  mice for all T cell epitopes tested
(Fig. 3, A and B). In contrast, JNK2 /  mice had signifi-
cantly higher total numbers of virus-specific CD8  T cells
for both epitopes while the difference in the number of
virus-specific CD4  T cells was not statistically significant
between JNK /  and JNK2 /  mice (P     0.2). Acute
VSV-infection gave similar results; smaller spleens and a sig-
nificantly reduced number of VSV-specific CD8  T cells
were observed in JNK1    mice compared with JNK   ,
and JNK2    mice, thus showing that a second virus caused
an equivalent phenotype to JNK1    mice infected with
LCMV (data not shown). When LCMV spleen memory
cells were quantified (60 d after inoculation), the percentage
of CD8  T cells was equivalent in all three groups.
After LCMV Infection, Apoptosis Is Significantly Increased in
JNK1 /  Mice. We wished to distinguish whether the re-
duced number of T lymphocytes in JNK1 /  mice during
acute LCMV infection was due to a defect in proliferation
or to enhanced apoptosis in JNK1 /  T cells. Conze and
colleagues in the accompanying paper report a decreased in
vitro proliferation for purified naive CD8  T cells in re-
Figure 2. The CD8  T cell compartment does not expand in JNK1 / 
mice during the primary LCMV infection in comparison to JNK2 /  and
JNK /  mice but equivalent number of CD8  T cell are noted 60 d later.
JNK / , JNK1 / , and JNK2 /  mice were injected intraperitoneally
with LCMV ARM 2   105 PFU. Uninfected spleen cells and spleen cells
7 (D7) or 60 d (D60) postinfection were stained for CD4 and CD8. Data
represent average values obtained from three animals per group and are
representative of two independent experiments. Values written in the dot
plots indicate the percentage of CD8  T cells and the percentage of
CD4  T cells
Figure 3. The number of virus-specific CD8  T cells and CD4  T cells is lower in JNK1 /  mice than in either JNK2 /  or JNK /  mice after
LCMV infection. JNK1 / , JNK2 / , and JNK /  mice were injected intraperitoneally with LCMV ARM, 2   105 PFU. 8 d after infection, spleen
were processed and stimulated for 5 h in vitro with virus-specific peptide GP aa 33–41, NP aa 396–404, GP aa 61–80, or NP aa 309–328. Cells were
then stained for surface CD4 or CD8 and intracellular IFN-  molecules. The number of virus-specific T cells was calculated from the number of total
spleen cells obtained per animal. Data represent average values obtained from three animals per group and are representative of two independent experi-
ments. (A) CD8  T cells; (B) CD4  T cells. *P   0.05 #P   0.052 when compared with JNK / .806 JNK1 and JNK2 in Viral-specific CD8  T Cell Expansion
sponse to antibodies to CD3 and CD28 in JNK1    com-
pared with JNK    mice, suggesting that JNK1   CD8  T
cells do not proliferate as much as JNK    after activation
via the TCR and costimulatory molecules. However, in
our hands, culture with anti-CD3 and anti-CD28 antibod-
ies of CD8   T cells from acutely infected mice led to
apoptosis of the majority of cells owing to their enhanced
state of activation (data not shown).
The percentage of activated splenic T cells dying during
the peak of the immune response were identified and
quantified using the CD44 marker, which is highly ex-
pressed by the expanding population of T cells (41). A
lower percentage of CD8  lymphocytes in JNK1 /  than
in JNK /  mice had acquired a CD44hi phenotype at 8 d
after LCMV infection (see Fig. 4 A). By comparison, a
higher percentage of JNK2 / CD8  T cells were CD44hi
compared with JNK /  cells. To evaluate apoptosis,
CD8 CD44hi were gated while excluding the dead cells
that were 7AAD positive, thereby allowing an evaluation
of the percentage of activated cells that were annexin-V
positive. As shown in Fig. 4, the percentage of cells under-
going apoptosis amongst CD8 CD44hi cells was signifi-
cantly greater in JNK1 /  mice than either JNK /  or
JNK2 /  mice. Increased apoptosis may likely account for
the decreased number of virus specific CD8  T cells found
in JNK1 /  mice. We looked at CD8 CD44lo cells and
found no significant difference in apoptosis between
JNK1    and JNK    cells (data not shown).
Analysis of CD4  T cells revealed fewer CD4  T cells
had acquired a CD44hi phenotype in JNK1 /  mice com-
pared with JNK /  mice during the acute phase, but simi-
lar proportions occurred in the JNK2 /  and JNK / 
mice. Gating on the CD4 CD44hi cells, a lower propor-
tion of JNK2 /  cells undergoing apoptosis (i.e., annexin-V
positive) was found compared with JNK /  and JNK1 / 
cells (Fig. 4 B).
To further characterize whether apoptotic pathways
were more active in JNK /  versus JNK / , the expres-
sion of antiapoptotic proteins bcl-2 or bcl-XL in CD8  T
cells from all three groups was evaluated. No significant
differences were observed in either bcl-2 or bcl-XL protein
expression by flow cytometry for CD8  T cells, for GP aa
33–41 or NP aa 396–404 tetramer-positive CD8  T cells
from JNK1 / , JNK2 / , and JNK /  mice (data not
shown) at 8 d after LCMV infection. In addition, no signif-
icant differences in levels of mRNA expression for bcl-2
and caspase genes families as measured by Rnase Protection
Assay (RPA) was observed in RNA from CD8  T cells
obtained from JNK1 / , JNK2 / , or JNK /  mice at day
8 after LCMV-inoculation (data not shown).
CD8  T Cell Expansion Is Enhanced in JNK2 /  Mice Af-
ter a Secondary Challenge with LCMV Compared with CD8 
T Cells from JNK /  Mice. To evaluate whether a defi-
ciency in JNK1 or JNK2 could affect the long-term mem-
ory of CD8  T cells, we measured the number of virus
specific T cells during the memory phase using an ex vivo
stimulation with LCMV-specific peptides GP aa 33–41
and NP aa 396–404. The number of memory cells mea-
sured at 60 d or more after initial LCMV infection was
higher in JNK2 /  mice but lower in JNK1 /  when
compared with JNK /  CD8  T memory cells. The
number of splenic CD8  T cells producing IFN-  after an
in vitro stimulation with GP aa 33–41 was 5.2   105  
2.3   104, 9.0   105   9.4   104, 6.8   105   9.2   104
for JNK1 / , JNK2 / , and JNK /  mice, respectively.
This trend of lower expansion of memory CD8  T cells in
JNK1 /  but a higher expansion in JNK2 /  when com-
pared with JNK /  mice was noted in all three experi-
ments and in all three individually studied mice, although
the differences were not statistically significant (P   0.2
for JNK2 /  versus JNK / , and P   0.5 for JNK1 / 
versus JNK / ).
Figure 4. During the acute infection, the number of
splenic CD8  T cells CD44hi is lower in JNK1 /  mice
than in JNK2 /  and JNK /  mice, and a greater propor-
tion of these cells from JNK1 /  undergo apoptosis.
JNK1 / , JNK2 / , and JNK /  animals were injected
intraperitoneally with LCMV ARM 2   105 PFU. 8 d af-
ter infection, spleen were processed to make single cell sus-
pension devoted of red blood cells and stained directly for
surface markers: CD4, CD8, and CD44 then annexin-V
and 7AA-D were added. Data represent average values ob-
tained from four animals per group and are representative
of two independent experiments. The percentage of CD8 
or CD4  that were CD44hi are shown in the left, that
were annexin V  cells among the CD8CD44hi or
CD4CD44hi on the right. (A) CD8  T cells. (B) CD4  T
cells. *P   0.05 compared with JNK / .807 Arbour et al.
JNK1 / , JNK2 / , and JNK /  mice were rechallenged
intravenously with Cl-13, a strain of LCMV that induces
persistent infection by aborting anti-LCMV–specific CD8 
T cell response after primary infection (42–44). In our stud-
ies, the immunosuppressive Cl-13 was given to mice who
already had undergone primary viral infection, cleared virus,
and established and maintained CD8  and CD4  anti-
LCMV memory T cells. LCMV-specific CD8  (Figs. 5 and
6) and CD4  T cells increased during the secondary chal-
lenge to a level comparable to the primary response. The ex-
pansion was observed for MHC class I–restricted epitopes
GP aa 33–41 and NP aa 396–404 as well as MHC class II–
restricted LCMV epitopes GP aa 61–80 and NP aa 309–328
(data for GP aa 33–41 shown on Fig. 5 A and data for NP aa
396–404 shown on Fig. 5 B). Similar to the primary re-
sponse, the expansion of CD8  T cells for both GP aa 33–
41 and NP aa 396–404 immunodominant epitopes was sig-
nificantly greater in JNK2 /  mice than in JNK /  mice,
suggesting that JNK2 plays a role in controlling of CD8  T
cell expansion in vivo. In contrast, despite the reduced burst
size of JNK1 /  mice during the primary response, the
number of virus-specific T cells after a secondary challenge
was comparable to that observed for JNK /  mice.
Discussion
Our results show for the first time that JNK1 and JNK2
MAP kinases play distinctly different roles in the activation
of CD8  T cells after viral infection. Although both
JNK1 /  and JNK2 /  mice cleared LCMV, the magni-
tude of their immune responses varied markedly. After an
acute LCMV infection, JNK1 /  mice did not show the
characteristic 5- to 10-fold expansion of the splenic CD8 
T cells observed in immunocompetent JNK /  or JNK2 / 
mice. JNK1 /  mice mounted LCMV-specific CTL re-
sponses, and their virus-specific CD8  T cells produced
IFN-  and IL-2. However, at the peak of the primary re-
sponse, the total number of JNK1 /  splenocytes was
 50% less than that of JNK /  mice and the number of vi-
rus specific CD8  and CD4  T cells was significantly re-
duced in JNK1 /  mice. Similar results were found with
VSV infection of JNK1    and JNK    mice suggesting
the generality of our finding that JNK1 and JNK2 MAP ki-
nases play distinctive and different roles in the activation of
T cells after viral infection.
After LCMV-infection, fewer JNK1 /  CD8  T cells
became activated and more of their CD8 CD44hi T cells
underwent apoptosis compared with the JNK / . This
would in part explain the impaired expansion of CD8  T
cells in these mice. Moreover, naive CD8  T cells from
JNK1     mice showed a decreased proliferation in re-
Figure 5. The number of splenic virus specific CD8  T cells and
CD4  T cells is lower in JNK1 /  mice than in either JNK2 /  or
JNK /  mice during the acute response but not during the secondary re-
sponse. JNK1 / , JNK2 / , and JNK /  mice were injected intraperito-
neally with LCMV ARM 2   105 PFU. Spleens were harvested at day 7,
8, 14, or 60 postinfection or 4 d after a challenge with Cl-13 (106 PFU
intravenously) in memory animals. Spleen cells were stimulated for 5 h in
vitro with virus specific peptides GP aa 33–41 or NP aa 396–404, then
stained for CD8 and intracellular IFN- . The number of virus specific T
cells was calculated from the number of total spleen cells obtained per an-
imal. Data represent average values obtained from three animals per group
and are representative of two independent experiments. *P   0.05, #P  
0.057 compared with JNK / .
Figure 6. The number of splenic virus specific CD8  T cells is greater
in JNK2 /  mice than in either JNK1 /  or JNK /  mice during the sec-
ondary response. JNK1 / , JNK2 / , and JNK /  mice were injected
intraperitoneally with LCMV ARM 2   105 PFU, rechallenged after 60 d
with Cl-13 (106 PFU intravenously), and spleens were harvested 4 d later.
Spleen cells were stimulated for 5 h in vitro with virus specific peptides
GP aa 33–41 or NP aa 396–404, then stained for CD8 and intracellular
IFN- . The number of virus-specific T cells was calculated from the
number of total spleen cells obtained per animal. Data represent average
values obtained from three animals per group and are representative of
three independent experiments. *P   0.05 when compared with JNK / .808 JNK1 and JNK2 in Viral-specific CD8  T Cell Expansion
sponse to antibodies to CD3 and CD28 compared with
JNK   , suggesting that in addition to the enhanced apop-
tosis, a decreased proliferation might contribute to the de-
creased number of virus specific CD8  T cells during cell
activation. Interestingly, the reduced CD8  T cell expan-
sion in JNK1 /  mice was observed only during the pri-
mary acute viral response, as the magnitude of their sec-
ondary (immune memory) response was similar to that of
the JNK /  mice. In contrast, JNK2-deficient mice
showed an increased expansion of virus-specific CD8  T
cells during the acute infection as well as during the sec-
ondary response. The enhanced expansion of virus specific
CD8  T cells coincided with an increased proportion of
CD8 CD44hi T cells compared with JNK /  mice.
Acute LCMV-infection triggers preferentially a Th1 re-
sponse rather than a Th2 response (45). Although it has
been reported that in vitro differentiation of Th0 JNK2 / 
CD4  T cells into Th1 is impaired (8), our results indicate
that in vivo JNK2 /  CD4  T cells were still capable of a
similar virus-specific Th1 response during an acute viral in-
fection, equivalent to CD4  T cell response of JNK / 
wild-type mice. Moreover, after acute LCMV infection,
JNK2 / CD4CD44hi T cells experienced less apoptosis,
suggesting that activated CD4  T cells may enhance the
antiviral response in JNK2 /  mice by providing higher
level of soluble mediators given that they were less inclined
to die than CD4  T cells from JNK /  mice. A second set
of JNK1 and JNK2 deficient mice have been developed
(46, 47). Analysis of the responses of mixed lymphocyte
populations of these animals led the authors to conclude
that JNK1 and 2 play a similar role in regulating IL-2 pro-
duction and T cell proliferation (47). Studies with purified
CD4  T cells from the mice of our present study showed
no role for JNK in these functions for CD4  T cells. How-
ever, as the studies of Sabapathy et al. used mixed cell pop-
ulations, it remained possible that CD8  T cell effects in
these cell populations influenced these results (47).
As mice deficient for either JNK1 or JNK2 showed a di-
vergent phenotype in the expansion of CD8  T cells dur-
ing the primary response to a viral infection, we propose
that these two MAP kinases have distinct roles in the acti-
vation of CD8  T cells. JNK1 /  and JNK2 /  mice show
a normal development of T and B lymphocytes (7, 8) and
the differences observed here occurred during the differen-
tiation of naive cells to fully activated cells. Many events
lead to the differentiation of CD8  T cells from a naive to
an activated state including the ligation of the TCR and
costimulatory molecules. Whereas naive T cells only ex-
press low levels of JNK, signals from both the TCR-CD3
complex and a costimulatory factor such as CD28 are nec-
essary for the activation of JNKs (48–50). Additionally,
many costimulatory molecules such as CD40, Ox40, 4–1BB,
CTLA-4, LFA-1, and CD27 mediate their signaling
through JNKs (12, 51, 52), but the results of these studies
did not discriminate among different JNKs. The precise
identification of signaling pathways blocked by the absence
of either JNK1 or JNK2 is complicated by numerous JNK
isoforms and at least a dozen upstream MAP kinase kinase
kinases that can activate the JNK pathway (3). Neverthe-
less, we speculate that JNK1 /  mice lack one or more
positive signals necessary for controlling the survival and
expansion of CD8  T cells during an immune response.
Given that we detected fully functional CD8  T cells in
both JNK1 /  and JNK2 /  mice as judged by antiviral
CTL activity, IL-2 production, IFN-  production, the im-
paired expansion of CD8  T cells in JNK1 / , and the en-
hanced expansion in JNK2 /  suggest a role for these
MAP kinases in controlling the degree (magnitude) rather
than the functionality of the immune response.
Among all costimulatory molecules with a signaling
pathway that could be partially or completely blocked in
JNK1 /  mice, 4–1BB is a compelling candidate. First,
4–1BB enhances CD8  T cell proliferation and IFN- 
(53–55) and is more important for the stimulation of CD8 
T cells rather than CD4  T cells (55, 56). Moreover, a role
in long-term CD8  T cell survival has been attributed to
this costimulatory molecule (56). Further, 4–1BB ligand
knockout mice responded to acute LCMV infection much
as JNK1 /  mice did. That is, 4–1BBL /  mice eliminated
LCMV with normal kinetics, but the expansion of their
CD8  T cells was two- to threefold lower than in wild-type
mice (28). Thus, the normal signaling pathway observed af-
ter the binding of 4–1BB to 4–1BBL could be affected by
the absence of the MAP kinases (e.g., JNK1). Alternatively,
other costimulatory pathways could be affected by the ab-
sence of either JNK1 or JNK2 with the 4–1BB/4–1BBL
pathway simply representing one possibility.
Conze et al. (9a) have assessed the in vitro functionality
of CD8  T cells in JNK1 /  and JNK2 /  mice after
polyclonal or mitogenic stimulation. The CD8  T cells
from JNK1 /  proliferated less than JNK /  cells, possibly
because of defective IL-2 production as well as decreased
expression of IL-2 receptor (CD25). JNK1 /  CD8  T
cells also produced a reduced amount of IFN-  compared
with JNK /  cells. These in vitro observations comple-
ment our in vivo findings of a decreased ability of CD8  T
cells to expand in JNK1 /  mice infected with LCMV.
However, we found no decrease in the amount of IL-2 or
IFN-  production or surface expression of CD25 by acti-
vated CD8  T cells noted in the in vitro system of Conze
et al. These discrepancies may reflect the different systems
studied (i.e., in vitro polyclonal/mitogenic stimulation
versus in vivo viral infection). During a viral infection, in-
teractions implicating CD3 and CD28 and other costimu-
latory molecules likely occur in the activation of CD8  T
cells.
Previously, JNK was established as a key player in the
polarization of CD4  T cells (7, 8). Our study now shows
that these MAP kinases are also important signaling path-
ways for activation of CD8  T cells. Further, we show that
individual members of the MAP kinase family have clearly
distinguishable functions in vivo. The model of LCMV in-
fection in JNK1 /  mice should prove valuable for further
evaluation of the specific contributions of JNK1, JNK2,
and various isoforms to the activation of T cells. These
properties may allow targeting of specific immune re-809 Arbour et al.
sponses to decrease CD8  T cell expansion without affect-
ing overall quality of the response.
We thank Dorian McGavern and Phyllis Minick for critically re-
viewing the manuscript. 
This work was supported by a National Institutes of Health grant
AI09484 to M.B.A. Oldstone; N. Arbour was supported by a post-
doctoral fellowship from the Canadian Institutes of Health, D. Nan-
iche by senior fellowship from the Leiper Trust, and D. Homann by
a senior post-doctoral fellowship from the Juvenile Diabetes Foun-
dation International (3-1999-629). R.A. Flavell and R.J. Davis are
Investigators of the Howard Hughes Medical Institute.
Submitted: 27 August 2001
Revised: 21 December 2001
Accepted: 8 February 2002
References
1. Whitmarsh, A.J., and R.J. Davis. 1996. Transcription factor
AP-1 regulation by mitogen-activated protein kinase signal
transduction pathways. J. Mol. Med. 74:589–607.
2. Ip, Y.T., and R.J. Davis. 1998. Signal transduction by the
c-Jun N-terminal kinase (JNK)—from inflammation to de-
velopment. Curr. Opin. Cell Biol. 10:205–219.
3. Chang, L., and M. Karin. 2001. Mammalian MAP kinase sig-
nalling cascades. Nature. 410:37–40.
4. Chow, C.W., C. Dong, R.A. Flavell, and R.J. Davis. 2000.
c-Jun NH(2)-terminal kinase inhibits targeting of the protein
phosphatase calcineurin to NFATc1.  Mol. Cell. Biol. 20:
5227–5234.
5. Chow, C.W., M. Rincon, J. Cavanagh, M. Dickens, and
R.J. Davis. 1997. Nuclear accumulation of NFAT4 opposed
by the JNK signal transduction pathway. Science. 278:1638–
1641.
6. Gupta, S., T. Barrett, A.J. Whitmarsh, J. Cavanagh, H.K.
Sluss, B. Derijard, and R.J. Davis. 1996. Selective interaction
of JNK protein kinase isoforms with transcription factors.
EMBO J. 15:2760–2770.
7. Dong, C., D.D. Yang, M. Wysk, A.J. Whitmarsh, R.J.
Davis, and R.A. Flavell. 1998. Defective T cell differentia-
tion in the absence of Jnk1. Science. 282:2092–2095.
8. Yang, D.D., D. Conze, A.J. Whitmarsh, T. Barrett, R.J.
Davis, M. Rincon, and R.A. Flavell. 1998. Differentiation of
CD4  T cells to Th1 cells requires MAP kinase JNK2. Im-
munity. 9:575–585.
9. Constant, S.L., C. Dong, D.D. Yang, M. Wysk, R.J. Davis,
and R.A. Flavell. 2000. JNK1 is required for T cell-mediated
immunity against Leishmania major infection.  J. Immunol.
165:2671–2676.
9a. Conze, D., T. Krahl, N. Kennedy, L. Weiss, J. Lumsden, P.
Hess, R.A. Flavell, G. Le Gros, R.J. Davis, and M. Rincon.
2002. c-Jun NH2-terminal kinase (JNK)1 and JNK2 have
distinct roles in CD8  T cell activation. J. Exp. Med. 195:
811–823.
10. Homann, D. 2001. Immunocytotherapy. Curr. Top. Microbiol.
Immunol. In press.
11. Slifka, M.K., and J.L. Whitton. 2000. Antigen-specific regu-
lation of T cell-mediated cytokine production. Immunity. 12:
451–457.
12. Whitmire, J.K., and R. Ahmed. 2000. Costimulation in anti-
viral immunity: differential requirements for CD4( ) and
CD8( ) T cell responses. Curr. Opin. Immunol. 12:448–455.
13. Byrne, J.A., and M.B. Oldstone. 1984. Biology of cloned cy-
totoxic T lymphocytes specific for lymphocytic choriomen-
ingitis virus: clearance of virus in vivo. J. Virol. 51:682–686.
14. Moskophidis, D., U. Assmann-Wischer, M.M. Simon, and F.
Lehmann-Grube. 1987. The immune response of the mouse
to lymphocytic choriomeningitis virus. V. High numbers of
cytolytic T lymphocytes are generated in the spleen during
acute infection. Eur. J. Immunol. 17:937–942.
15. Zarozinski, C.C., and R.M. Welsh. 1997. Minimal bystander
activation of CD8 T cells during the virus-induced poly-
clonal T cell response. J. Exp. Med. 185:1629–1639.
16. Murali-Krishna, K., J.D. Altman, M. Suresh, D.J. Sourdive,
A.J. Zajac, J.D. Miller, J. Slansky, and R. Ahmed. 1998.
Counting antigen-specific CD8 T cells: a reevaluation of by-
stander activation during viral infection. Immunity. 8:177–187.
17. Butz, E.A., and M.J. Bevan. 1998. Massive expansion of anti-
gen-specific CD8  T cells during an acute virus infection.
Immunity. 8:167–175.
18. Homann, D., L. Teyton, and M.B. Oldstone. 2001. Differ-
ential regulation of antiviral T-cell immunity results in stable
CD8  but declining CD4  T-cell memory. Nat. Med.
7:913–919.
19. Varga, S.M., and R.M. Welsh. 1998. Detection of a high fre-
quency of virus-specific CD4  T cells during acute infection
with lymphocytic choriomeningitis virus. J. Immunol. 161:
3215–3218.
20. Selin, L.K., K. Vergilis, R.M. Welsh, and S.R. Nahill. 1996.
Reduction of otherwise remarkably stable virus-specific cy-
totoxic T lymphocyte memory by heterologous viral infec-
tions. J. Exp. Med. 183:2489–2499.
21. Lau, L.L., B.D. Jamieson, T. Somasundaram, and R. Ahmed.
1994. Cytotoxic T-cell memory without antigen.  Nature.
369:648–652.
22. Asano, M.S., and R. Ahmed. 1996. CD8 T cell memory in B
cell-deficient mice. J. Exp. Med. 183:2165–2174.
23. Berger, D.P., D. Naniche, M.T. Crowley, P.A. Koni, R.A.
Flavell, and M.B. Oldstone. 1999. Lymphotoxin-beta-defi-
cient mice show defective antiviral immunity. Virology. 260:
136–147.
24. Borrow, P., A. Tishon, S. Lee, J. Xu, I.S. Grewal, M.B. Old-
stone, and R.A. Flavell. 1996. CD40L-deficient mice show
deficits in antiviral immunity and have an impaired memory
CD8  CTL response. J. Exp. Med. 183:2129–2142.
25. Cousens, L.P., J.S. Orange, and C.A. Biron. 1995. Endoge-
nous IL-2 contributes to T cell expansion and IFN-gamma
production during lymphocytic choriomeningitis virus infec-
tion. J. Immunol. 155:5690–5699.
26. Orange, J.S., and C.A. Biron. 1996. An absolute and re-
stricted requirement for IL-12 in natural killer cell IFN-
gamma production and antiviral defense. Studies of natural
killer and T cell responses in contrasting viral infections. J.
Immunol. 156:1138–1142.
27. van den Broek, M.F., U. Muller, S. Huang, M. Aguet, and
R.M. Zinkernagel. 1995. Antiviral defense in mice lacking
both alpha/beta and gamma interferon receptors. J. Virol. 69:
4792–4796.
28. Tan, J.T., J.K. Whitmire, R. Ahmed, T.C. Pearson, and C.P.
Larsen. 1999. 4-1BB ligand, a member of the TNF family, is
important for the generation of antiviral CD8 T cell re-
sponses. J. Immunol. 163:4859–4868.
29. Andreasen, S.O., J.E. Christensen, O. Marker, and A.R.
Thomsen. 2000. Role of CD40 ligand and CD28 in induc-
tion and maintenance of antiviral CD8  effector T cell re-810 JNK1 and JNK2 in Viral-specific CD8  T Cell Expansion
sponses. J. Immunol. 164:3689–3697.
30. Zimmermann, C., P. Seiler, P. Lane, and R.M. Zinkernagel.
1997. Antiviral immune responses in CTLA4 transgenic
mice. J. Virol. 71:1802–1807.
31. Gallimore, A., A. Glithero, A. Godkin, A.C. Tissot, A.
Pluckthun, T. Elliott, H. Hengartner, and R. Zinkernagel.
1998. Induction and exhaustion of lymphocytic choriomen-
ingitis virus-specific cytotoxic T lymphocytes visualized us-
ing soluble tetrameric major histocompatibility complex class
I-peptide complexes. J. Exp. Med. 187:1383–1393.
32. Dutko, F.J., and M.B. Oldstone. 1983. Genomic and biolog-
ical variation among commonly used lymphocytic chorio-
meningitis virus strains. J. Gen. Virol. 64:1689–1698.
33. Salvato, M., E. Shimomaye, P. Southern, and M.B. Old-
stone. 1988. Virus-lymphocyte interactions. IV. Molecular
characterization of LCMV Armstrong (CTL ) small ge-
nomic segment and that of its variant, Clone 13 (CTL-). Vi-
rology. 164:517–522.
34. Homann, D., A. Tishon, D.P. Berger, W.O. Weigle, M.G.
von Herrath, and M.B. Oldstone. 1998. Evidence for an un-
derlying CD4 helper and CD8 T-cell defect in B-cell-defi-
cient mice: failure to clear persistent virus infection after
adoptive immunotherapy with virus-specific memory cells
from muMT/muMT mice. J. Virol. 72:9208–9216.
35. Kagi, D., B. Ledermann, K. Burki, P. Seiler, B. Odermatt,
K.J. Olsen, E.R. Podack, R.M. Zinkernagel, and H. Hen-
gartner. 1994. Cytotoxicity mediated by T cells and natural
killer cells is greatly impaired in perforin-deficient mice. Na-
ture. 369:31–37.
36. Walsh, C.M., M. Matloubian, C.C. Liu, R. Ueda, C.G.
Kurahara, J.L. Christensen, M.T. Huang, J.D. Young, R.
Ahmed, and W.R. Clark. 1994. Immune function in mice
lacking the perforin gene. Proc. Natl. Acad. Sci. USA. 91:
10854–10858.
37. Ahmed, R., J.A. Byrne, and M.B. Oldstone. 1984. Virus
specificity of cytotoxic T lymphocytes generated during
acute lymphocytic choriomeningitis virus infection: role of
the H-2 region in determining cross-reactivity for different
lymphocytic choriomeningitis virus strains. J. Virol. 51:34–
41.
38. Yanagi, Y., A. Tishon, H. Lewicki, B.A. Cubitt, and M.B.
Oldstone. 1992. Diversity of T-cell receptors in virus-specific
cytotoxic T lymphocytes recognizing three distinct viral
epitopes restricted by a single major histocompatibility com-
plex molecule. J. Virol. 66:2527–2531.
39. Chen, C.Y., R. Gherzi, J.S. Andersen, G. Gaietta, K. Jur-
chott, H.D. Royer, M. Mann, and M. Karin. 2000. Nucleo-
lin and YB-1 are required for JNK-mediated interleukin-2
mRNA stabilization during T-cell activation. Genes Dev. 14:
1236–1248.
40. Oxenius, A., M.F. Bachmann, P.G. Ashton-Rickardt, S.
Tonegawa, R.M. Zinkernagel, and H. Hengartner. 1995.
Presentation of endogenous viral proteins in association with
major histocompatibility complex class II: on the role of in-
tracellular compartmentalization, invariant chain and the
TAP transporter system. Eur. J. Immunol. 25:3402–3411.
41. Whitmire, J.K., M.S. Asano, K. Murali-Krishna, M. Suresh,
and R. Ahmed. 1998. Long-term CD4 Th1 and Th2 mem-
ory following acute lymphocytic choriomeningitis virus in-
fection. J. Virol. 72:8281–8288.
42. Sevilla, N., S. Kunz, A. Holz, H. Lewicki, D. Homann, H.
Yamada, K.P. Campbell, J.C. de La Torre, and M.B. Old-
stone. 2000. Immunosuppression and resultant viral persis-
tence by specific viral targeting of dendritic cells. J. Exp. Med.
192:1249–1260.
43. Borrow, P., C.F. Evans, and M.B. Oldstone. 1995. Virus-
induced immunosuppression: immune system-mediated de-
struction of virus-infected dendritic cells results in generalized
immune suppression. J. Virol. 69:1059–1070.
44. Ahmed, R., A. Salmi, L.D. Butler, J.M. Chiller, and M.B.
Oldstone. 1984. Selection of genetic variants of lymphocytic
choriomeningitis virus in spleens of persistently infected
mice. Role in suppression of cytotoxic T lymphocyte re-
sponse and viral persistence. J. Exp. Med. 160:521–540.
45. Varga, S.M., and R.M. Welsh. 2000. High frequency of vi-
rus-specific interleukin-2-producing CD4( ) T cells and
Th1 dominance during lymphocytic choriomeningitis virus
infection. J. Virol. 74:4429–4432.
46. Sabapathy, K., Y. Hu, T. Kallunki, M. Schreiber, J.P. David,
W. Jochum, E.F. Wagner, and M. Karin. 1999. JNK2 is re-
quired for efficient T-cell activation and apoptosis but not for
normal lymphocyte development. Curr. Biol. 9:116–125.
47. Sabapathy, K., T. Kallunki, J.P. David, I. Graef, M. Karin,
and E.F. Wagner. 2001. c-Jun NH(2)-Terminal Kinase
(JNK)1 and JNK2 have similar and stage-dependent roles in
regulating T cell apoptosis and proliferation. J. Exp. Med.
193:317–328.
48. Su, B., E. Jacinto, M. Hibi, T. Kallunki, M. Karin, and Y.
Ben-Neriah. 1994. JNK is involved in signal integration dur-
ing costimulation of T lymphocytes. Cell. 77:727–736.
49. Rincon, M., and R.A. Flavell. 1994. AP-1 transcriptional activ-
ity requires both T-cell receptor-mediated and co-stimulatory
signals in primary T lymphocytes. EMBO J. 13:4370–4381.
50. Weiss, L., A.J. Whitmarsh, D.D. Yang, M. Rincon, R.J.
Davis, and R.A. Flavell. 2000. Regulation of c-Jun NH(2)-
terminal kinase (Jnk) gene expression during T cell activa-
tion. J. Exp. Med. 191:139–146.
51. Calvo, C.R., D. Amsen, and A.M. Kruisbeek. 1997. Cyto-
toxic T lymphocyte antigen 4 (CTLA-4) interferes with ex-
tracellular signal-regulated kinase (ERK) and Jun NH2-ter-
minal kinase (JNK) activation, but does not affect
phosphorylation of T cell receptor zeta and ZAP70. J. Exp.
Med. 186:1645–1653.
52. Akiba, H., H. Nakano, S. Nishinaka, M. Shindo, T. Kobata,
M. Atsuta, C. Morimoto, C.F. Ware, N.L. Malinin, D.
Wallach, et al. 1998. CD27, a member of the tumor necrosis
factor receptor superfamily, activates NF-kappaB and stress-
activated protein kinase/c-Jun N-terminal kinase via
TRAF2, TRAF5, and NF-kappaB-inducing kinase. J. Biol.
Chem. 273:13353–13358.
53. Kim, H.H., K. Kwack, and Z.H. Lee. 2000. Activation of
c-jun N-terminal kinase by 4-1BB (CD137), a T cell co-
stimulatory molecule. Mol. Cells. 10:247–252.
54. Cannons, J.L., K.P. Hoeflich, J.R. Woodgett, and T.H.
Watts. 1999. Role of the stress kinase pathway in signaling
via the T cell costimulatory receptor 4-1BB. J. Immunol. 163:
2990–2998.
55. Shuford, W.W., K. Klussman, D.D. Tritchler, D.T. Loo, J.
Chalupny, A.W. Siadak, T.J. Brown, J. Emswiler, H.
Raecho, C.P. Larsen, et al. 1997. 4-1BB costimulatory sig-
nals preferentially induce CD8  T cell proliferation and lead
to the amplification in vivo of cytotoxic T cell responses. J.
Exp. Med. 186:47–55.
56. Takahashi, C., R.S. Mittler, and A.T. Vella. 1999. Cutting
edge: 4-1BB is a bona fide CD8 T cell survival signal. J. Im-
munol. 162:5037–5040.